๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Lymphoma

A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma๏ผˆKeyplus-001๏ผ‰ NCT05357651Phase 11 site๐Ÿ“ Shanghai L & L Bio Co., Ltd., Ningbo, China ยท Tests: LB1410 A Real World Study of Ensartinib in Advanced ALK-positive NSCLC NCT05498064n/a1 site๐Ÿ“ Beijing Peking Union Medical College Hospital ยท Tests: Ensartinib Sample Collection and Tracking for the Developmental Therapeutics Clinic NCT03269578n/a1 site๐Ÿ“ Bethesda National Cancer Institute (NCI) Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia NCT05281809Phase 21 site๐Ÿ“ Pittsburgh John Lister ยท Tests: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE) NCT06534463n/a1 site๐Ÿ“ Shanghai Ruijin Hospital ยท Tests: All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the reโ€ฆ Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study NCT05846763n/a1 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia NCT05827549Phase 210 sites๐Ÿ“ Daegu๐Ÿ“ Daejeon๐Ÿ“ Hwasun Ho Joon Im ยท Tests: Reinduction(4weeks), Cosolodation 1st(3weeks), Consolidation 2nd(3weeks), Blinatumomab 1st(High Risk Group)_4 Weeks, Blโ€ฆ Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention NCT06686108Phase 21 site๐Ÿ“ Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Scโ€ฆ ยท Tests: Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: CD180 CART Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites๐Ÿ“ Chicago๐Ÿ“ Evanston๐Ÿ“ Providence AvenCell Therapeutics, Inc. ยท Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06689917NA1 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: JY231 Injection DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) NCT07059650Phase 1, Phase 213 sites๐Ÿ“ Beijing๐Ÿ“ Changsha๐Ÿ“ Chengdu Dizal Pharmaceuticals ยท Tests: DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR Nurture by Nature Feasibility Study NCT07780123NA1 site๐Ÿ“ Frederiksberg Ina Olmer Specht ยท Tests: Nature-base intervention This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946Phase 16 sites๐Ÿ“ Duarte๐Ÿ“ St Louis๐Ÿ“ Buffalo LTZ Therapeutics, Inc. ยท Tests: LTZ-301, LTZ-301, LTZ-301 CAV Regimen for R/R Ph- B-ALL NCT05657652NA1 site๐Ÿ“ Suzhou The First Affiliated Hospital of Soochow University ยท Tests: cladribine, cytarabine,venetoclax Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma NCT07299149Phase 22 sites๐Ÿ“ Tianjin๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: Induction Therapy: Zanubrutinib, obinutuzumab, lenalidomide, Maintenance therapy: Zanubrutinib, lenalidomide A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites๐Ÿ“ Santander๐Ÿ“ Salamanca๐Ÿ“ Barcelona IDP Discovery Pharma S.L. ยท Tests: IDP-121 5HTP Regulation Of Asthma In Children NCT04160910Phase 21 site๐Ÿ“ Indianapolis Indiana University ยท Tests: 5-Hydroxytryptophan, Placebo Pediatric Orthopaedic Implant Safety & Efficacy NCT05361980n/a1 site๐Ÿ“ Vancouver University of British Columbia ยท Tests: Pediatric orthopaedic implant A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma NCT07044050Phase 11 site๐Ÿ“ Montpellier Emercell SAS ยท Tests: allogenic natural killer cells Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites๐Ÿ“ Houston๐Ÿ“ Houston Baylor College of Medicine ยท Tests: C7R.CD30.CAR-EBVST cells Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma NCT07763210Phase 21 site๐Ÿ“ Nashville Vanderbilt-Ingram Cancer Center ยท Tests: Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease NCT05907759Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: Daratumumab SC Ovarian Hyperstimulation Syndrome Prevention NCT06739759NA2 sites๐Ÿ“ Giza๐Ÿ“ Giza Aljazeera Hospital ยท Tests: Antagonist protocol for IVF, Modified Agonist protocol for IVF with additive treatments as HCQ Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry NCT04220970n/a31 sites๐Ÿ“ Bruges๐Ÿ“ Brussels๐Ÿ“ Brussels The Lymphoma Academic Research Organisation ยท Tests: BIA-ALCL Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL NCT07234487Phase 23 sites๐Ÿ“ Moscow๐Ÿ“ Moscow๐Ÿ“ Saint Petersburg St. Petersburg State Pavlov Medical University ยท Tests: Nivo-AVD, BEACOPP-like A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 NCT07546760Phase 14 sites๐Ÿ“ Chandler๐Ÿ“ Rialto๐Ÿ“ Miami Lakes AstraZeneca ยท Tests: AZD6234, AZD9550 Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial NCT06355583Phase 28 sites๐Ÿ“ Birmingham๐Ÿ“ Leeds๐Ÿ“ London Imperial College London ยท Tests: EBX-102, Placebo Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies NCT06508775NA7 sites๐Ÿ“ Berlin๐Ÿ“ Cologne๐Ÿ“ Erlangen Miltenyi Biomedicine GmbH ยท Tests: MB-CART19.1, MB-CART20.1, MB-CART2019.1 Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT07572136Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: TSLPR-CART, Cyclophosphamide, Fludarabine
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy